🔗 Share this article

While the United States proceeds with unprecedented revisions to its vaccination recommendations, an unexpected name has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based physician and public health researcher who rose to prominence by questioning Covid vaccines throughout the global health crisis and has zeroed in on potential fatalities following Covid vaccination in her recent time at the FDA.

Planned Changes to Pediatric Vaccine Program

Public health authorities were set to unveil sweeping revisions to the childhood vaccine schedule in December, bringing the US with the Danish vaccine program, sources say – a substantial departure that would place the US at odds with many the world with little proof for public health gain. The planned update has been delayed until the coming year.

Rather than Vinay Prasad, Tracy Beth Høeg is set to present at the event. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the division this year.

A New Direction at the Regulatory Body

This interim role could signify a tighter collaboration between the pharmaceutical and biologics centers as Dr. Høeg and Dr. Prasad solidify control at the agency – and it signals a greater focus upon reevaluating long-standing vaccines at the FDA.

Høeg has repeatedly called for ending specific childhood immunization guidelines in the US so as to align more similar to the Danish model, a country with universal health coverage and a population approximately the population of Wisconsin’s.

To date public appearances, she has persisted in emphasizing on immunizations – typically the domain of Prasad, director of the FDA’s CBER – rather than medication approval.

Questions Over Qualifications

Dr. Høeg has little discernible track record in pharmaceutical research, oversight or management, which has been standard for previous leaders of the CBER. She has been employed at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“She appears not to have the requisite experience” for overseeing the CDER, said Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in running a sizeable institution. She is not an expert in industry regulation.”

Previous directors of the center would “be deeply familiar with regulatory frameworks and the research of medication creation”, noted Dr. Janet Woodcock. “Clearly, she doesn’t have the kind of background that former directors who headed CBER have had.”

The drug center has an immense portfolio at the agency, she pointed out.

“Everybody just focuses on the novel medication approvals, but the off-patent medication office approves a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and other areas, and each of these have to be looked after,” Woodcock noted. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to bite you.”

There is also, a major leadership component to the role, which supervises in excess of 5,000 personnel. “It is a massive management job, if you execute it properly,” Woodcock added.

Response and Controversial Initiatives

When asked about questions about Dr. Høeg's qualifications and whether this selection signifies more teamwork among regulatory chiefs on immunizations, a spokesperson said that the “questions rely on inaccurate premises”.

“Her resume is consistent with the duties of her role,” the representative explained, citing the period Høeg spent advising the agency head on “medication safety and oversight research, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s controversial expedited review system, a controversial one-day medication authorization process that apparently worried her preceding directors. “How are these drugs being chosen for this voucher program? Who makes the choices?” Dr. Howard said. “There is a lot of lack of transparency going on at the agency right now.”

In general, he said, “the FDA appears to be shifting towards laxer oversight of all drugs, except for vaccines.”

Public History on Immunizations

With immunizations, Høeg has a more established, if concerning, past, some experts said. She published a research paper using unverified crowd-sourced reports to assess the incidence of myocarditis after Covid immunization. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccines are more dangerous than they are.

Among her “desired changes” for the current federal leadership included altering rules for recently developed shots and ending “non-essential” immunizations, she said following the vote on a podcast. At the agency, Dr. Høeg has according to sources proposed excluding teenage boys from obtaining COVID-19 vaccines.

“She’s an thorough ideologue who begins with her conclusions and reverse-engineers to fit the data in a very disingenuous, untruthful way,” Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of other contrarians, {like|